Markets may be at all-time highs, but that does not mean every bank-backed stock is a buy. Alpesh Patel OBE reviews 25 top-tier ideas from the world’s biggest banks, using momentum, quality and valuation checks to separate potential opportunities from stocks where the brokers may be ahead of the chart.

All Time Highs

Well the crazy news is that we’re at all-time highs, which, of course, is a little bit like that parcel of land my uncle has in the north of England for the last 30 years.

He discovered that, instead of all the businesses he set up and built, if he just held on to the land, did nothing else, and then sold it 30 years later, that would have been the biggest success of all. The stock markets feel like that: there’s a lot of heat, not much light, but one thing’s clear: all-time highs are all-time highs and sitting back and enjoying the sunshine is the easiest hard money you’ll ever make.

I narrowly missed out on winning Finfluencer Awards Best Economist. However I did get to meet a representative from ShareScope so that was really nice. We should probably do a ShareScope x Alpesh Patel event at some point.

In this newsletter I’ll go through what the biggest banks are saying and, of course, my take. More importantly, a few of the charts from ShareScope as well

I also read that if the stock markets had four up years, which it looks like it will this year, then the fifth year is usually up as well. This is just getting ridiculous now.

Sadly people confuse price rises with valuation. They look at the numerator not the denominator in a ratio. That’s no great surprise and so they think, in general, by the way, the market must be overvalued. Parts of it always have been. But growth very much looks like the default state. Whilst we’re well aware that corrections of a 10% drop are normal as well, holding those two apparently diametrically opposed views at the same time is way beyond the human brain. Thankfully we now have AI.

What the World’s Biggest Banks Are Backing Right Now

A 25-stock top tier from seven global wealth-management banks — October 2026

Full stock-by-stock analysis available exclusively to Alpesh Patel Special Edition subscribers.

THE METHOD — WHY THIS LIST EXISTS

Every month the world’s largest wealth-management banks publish their ratings, and every month most private investors ignore them. That is a mistake. UBS, Barclays, Citi, Goldman Sachs, JP Morgan, Morgan Stanley and Bank of America manage trillions for their private clients. When their analysts cluster around a stock, the money tends to follow. Each month I take the stocks these banks rate a buy and run every one through my own screen: the chart, the MACD, the quality metrics and live analyst sentiment. The banks do the discovery. We do the discipline.

A buy rating is a useful starting point, not a finishing line. Ratings change, banks are often wrong together, and a great business can still be at the wrong point in its momentum cycle. My job is to separate the stocks where the banks’ conviction, the fundamentals and the chart all agree from the ones where you would be buying an opinion on a falling chart.

This month I filtered more than 110 bank-rated stocks down to a top tier of 25, with a further 87 on the watchlist. The backdrop is a Federal Reserve that has started raising rates again, September inflation at 3.7%, oil near $100, a 10-year Treasury yield above 5%, and a sharp mid-October sell-off in AI stocks. Several of the 25 are textbook setups. Several others are quality businesses where the chart has not caught up with the brokers. Knowing which is which is what the full analysis provides.

The banks narrow the universe. The MACD tells you whether the money is moving with them right now. Use both — neither alone is sufficient.

OCTOBER 2026 — WHAT IS DRIVING THE LIST

Four macro facts cut across virtually every position this month. Understanding them first stops you reading individual situations in isolation.

• Rates are rising again: The Federal Reserve raised its target range by a quarter point on 16 September 2026 to 3.75–4.00%, and the next meeting falls in the last week of October. The US 10-year Treasury yield touched 5.31% on 5 October, its highest level in 24 years, and closed the week of 16 October at 5.10%.
• Inflation is back in the data: US consumer prices rose 0.6% in September and 3.7% over 12 months. Core inflation is calmer at 2.6%, but producer prices jumped 1.3% in the month, the largest monthly rise since March 2022.
• Oil is near $100: Crude closed at $99.02 on 16 October, up more than 72% this year on geopolitical tensions, and US petrol averaged $4.33 a gallon.
• The tape rotated in mid-October: The S&P 500 closed the week of 16 October at 7,659, down 1.95% on the week but still up 11.9% this year. The Nasdaq fell 4.5% and technology dropped 6.6% on AI valuation worries, while consumer staples, healthcare and energy led.
• The banks are in good shape: Goldman Sachs’ third-quarter equities trading revenue rose 72%, JP Morgan’s 49%, and Citigroup reported its best third-quarter revenue in a decade. The US-China Busan trade truce has also been extended to 10 January 2027.

WHAT THE FRAMEWORK FOUND

Each top-tier stock receives one of three statuses under my framework: CONFIRMED where both MACD timeframes support the fundamentals, MIXED where the fundamentals qualify but the monthly MACD has not yet turned, and COMPROMISED where the monthly regime is bearish and capital preservation takes priority, whatever the brokers say. This month: 15 CONFIRMED, 9 MIXED and 1 COMPROMISED. The COMPROMISED name carries a bank buy rating and passes my quality screen, which is precisely why the framework exists.

INSURANCE, REINSURANCE & ASSET MANAGERS — 7 POSITIONS

Seven of the 25 top-tier names. Scores 7 to 9. Projections +19% to +27%. Most trade 30–65% below fair-value estimates. Three CONFIRMED, four MIXED.

This is the biggest single message from the banks this month. Insurers hold premiums before claims are paid, and with the 10-year Treasury yield above 5%, that float earns more than it has in two decades. One name in this group scores 9 out of 10 on my VGI quality screen, has both MACD timeframes rising, and has not had a sell rating in a year. Another has the biggest buy wall in the whole report, with six banks reiterating on the same day, yet its monthly MACD is still below signal.

MORE AVAILABLE IN THE ALPESH PATEL SPECIAL EDITION NEWSLETTER – SUBSCRIBERS ONLY. EXISTING APSE SUBSCRIBERS PLEASE REFER TO LATEST NEWSLETTER.Insurance & Asset Managers — Full Analysis— The VGI 9 reinsurer trading around 65% below fair value, and why both timeframes now agree — The stock six banks rated a buy on the same day, and the one MACD cross to wait for — Which of the four MIXED names is closest to turning CONFIRMED — Exact MACD reads, statuses, 12-month chart projections and analyst coverage for all seven Upgrade at sharescope.co.uk/alpeshpatel

AI HARDWARE, SEMICONDUCTORS & SOFTWARE — 4 POSITIONS

Scores 7 to 8. Projections +50% to +60%, the highest of any group. All four CONFIRMED on the monthly.

All four were caught in the mid-October AI sell-off, when the Nasdaq fell 4.5% in a week and technology dropped 6.6%. One fell almost 12% in that week alone, despite earnings forecast to grow at nearly 40% a year and 112 bank buy ratings in 12 months without a single sell. This is exactly the situation the framework is built for: a bullish monthly climate with bad weekly weather.

MORE AVAILABLE IN THE ALPESH PATEL SPECIAL EDITION NEWSLETTER – SUBSCRIBERS ONLY. EXISTING APSE SUBSCRIBERS PLEASE REFER TO LATEST NEWSLETTER.AI Hardware & Semiconductors — Full Analysis— The chip stock that fell 12% in a week while its monthly MACD kept rising — The data-centre connector maker with 36 buys and no sells, and the weekly trigger to watch — The software name with the best chart and the weakest forward numbers — Exact MACD reads, prices and 12-month chart projections for all four Upgrade at sharescope.co.uk/alpeshpatel

HEALTHCARE — 2 POSITIONS

Scores 8 to 9. Projections +21% to +28%. Both CONFIRMED.

When money left technology in mid-October, healthcare was one of the sectors it went to. These are the two most attractive risk-reward setups in the report. One is a VGI 9 with both MACD timeframes rising and six bank buy ratings in a single week. The other is a textbook recovery from a deep monthly washout, trading almost 68% below fair value with two broker upgrades in a fortnight.

MORE AVAILABLE IN THE ALPESH PATEL SPECIAL EDITION NEWSLETTER – SUBSCRIBERS ONLY. EXISTING APSE SUBSCRIBERS PLEASE REFER TO LATEST NEWSLETTER.Healthcare — Full Analysis— The cleanest chart in the entire report, and the balance-sheet caveat that sets the position size — The biotech recovery the brokers are only now starting to upgrade — Exact MACD reads, fair-value gaps and analyst moves for both Upgrade at sharescope.co.uk/alpeshpatel

INDUSTRIALS, ENERGY & MATERIALS — 7 POSITIONS

Scores 7 to 8. Projections +23% to +75%. Four CONFIRMED, two MIXED, one COMPROMISED.

The broadest group in the report, from solar wiring and gas pipelines to rail equipment, building systems and industrial gases. It holds the two highest projections in the top tier, both above 70%. It also holds the one COMPROMISED name this month: a quality business with a bank buy rating whose monthly and weekly MACD are now both falling.

MORE AVAILABLE IN THE ALPESH PATEL SPECIAL EDITION NEWSLETTER – SUBSCRIBERS ONLY. EXISTING APSE SUBSCRIBERS PLEASE REFER TO LATEST NEWSLETTER.Industrials, Energy & Materials — Full Analysis— The small-cap solar supplier rising from oversold, with the highest projection in the report — The energy infrastructure name with 50 buy ratings and no sells as oil nears $100 — The COMPROMISED stock, and why a buy rating on a falling chart is not a trade — Exact MACD reads, statuses and 12-month chart projections for all seven Upgrade at sharescope.co.uk/alpeshpatel

CONSUMER & LATIN AMERICAN FINANCIALS — 5 POSITIONS

All five score 7. Projections +19% to +45%. Two CONFIRMED, three MIXED.

The most varied group in the report: two Brazilian financials, an Italian luxury house, a US car retailer and a household-name apparel brand. One Brazilian name has just turned its monthly MACD up from below zero, with four banks rating it a buy in the past month. The apparel brand collected seven buy ratings in a single day, yet its monthly MACD has slipped below signal. The brokers are ahead of the chart.

MORE AVAILABLE IN THE ALPESH PATEL SPECIAL EDITION NEWSLETTER – SUBSCRIBERS ONLY. EXISTING APSE SUBSCRIBERS PLEASE REFER TO LATEST NEWSLETTER.Consumer & Latin America — Full Analysis— The Brazilian platform whose monthly just turned up from oversold — The luxury name with a flawless balance sheet and no risk flags — Why seven buy ratings in a day are not enough on their own — Exact MACD reads, statuses and 12-month chart projections for all five Upgrade at sharescope.co.uk/alpeshpatel

ALL 25 TOP-TIER POSITIONS — STATUS AT A GLANCE

Below is the complete top tier with ticker, sector group and my framework status. The full write-up on every name, including exact MACD readings, VGI score, analyst coverage, risk flags and 12-month chart projection, is available to Special Edition subscribers.

Ticker	Company	Sector	Status	Detail
RGA	Reinsurance Group of America	Insurance & Asset Mgmt	Confirmed ✓	Full analysis: APSE only 🔒
VOYA	Voya Financial	Insurance & Asset Mgmt	Confirmed ✓	Full analysis: APSE only 🔒
AIZ	Assurant	Insurance & Asset Mgmt	Confirmed ✓	Full analysis: APSE only 🔒
MRSH	Marsh & McLennan	Insurance & Asset Mgmt	Mixed →	Full analysis: APSE only 🔒
AJG	Arthur J. Gallagher	Insurance & Asset Mgmt	Mixed →	Full analysis: APSE only 🔒
ACGL	Arch Capital Group	Insurance & Asset Mgmt	Mixed →	Full analysis: APSE only 🔒
BLK	BlackRock	Insurance & Asset Mgmt	Mixed →	Full analysis: APSE only 🔒
AMD	Advanced Micro Devices	AI & Semis	Confirmed ✓	Full analysis: APSE only 🔒
TSM	Taiwan Semiconductor	AI & Semis	Confirmed ✓	Full analysis: APSE only 🔒
APH	Amphenol	AI & Semis	Confirmed ✓	Full analysis: APSE only 🔒
TWLO	Twilio	AI & Semis	Confirmed ✓	Full analysis: APSE only 🔒
ABBV	AbbVie	Healthcare	Confirmed ✓	Full analysis: APSE only 🔒
REGN	Regeneron Pharmaceuticals	Healthcare	Confirmed ✓	Full analysis: APSE only 🔒
SHLS	Shoals Technologies	Industrials & Energy	Confirmed ✓	Full analysis: APSE only 🔒
TRGP	Targa Resources	Industrials & Energy	Confirmed ✓	Full analysis: APSE only 🔒
WAB	Wabtec	Industrials & Energy	Confirmed ✓	Full analysis: APSE only 🔒
JCI	Johnson Controls	Industrials & Energy	Confirmed ✓	Full analysis: APSE only 🔒
DD	DuPont de Nemours	Industrials & Energy	Mixed →	Full analysis: APSE only 🔒
LIN	Linde	Industrials & Energy	Mixed →	Full analysis: APSE only 🔒
VMC	Vulcan Materials	Industrials & Energy	Compromised ▼	Full analysis: APSE only 🔒
XP	XP Inc	Consumer & LatAm	Confirmed ✓	Full analysis: APSE only 🔒
ZGN	Ermenegildo Zegna	Consumer & LatAm	Confirmed ✓	Full analysis: APSE only 🔒
INTR	Inter & Co	Consumer & LatAm	Mixed →	Full analysis: APSE only 🔒
LAD	Lithia Motors	Consumer & LatAm	Mixed →	Full analysis: APSE only 🔒
LEVI	Levi Strauss	Consumer & LatAm	Mixed →	Full analysis: APSE only 🔒

HOW TO USE SHARESCOPE ON THIS LIST

You do not need the full analysis to start working with this universe in ShareScope. Here is a simple starting workflow:

• Pull up the monthly chart first — before reading any analyst note or fair-value estimate. In my framework the monthly is the climate and the weekly is the weather. When they conflict, the monthly wins.
• Add MACD (12,26,9) on both timeframes: monthly above signal and rising means the climate supports the position. Monthly below signal and falling means capital preservation comes first, however many banks rate it a buy.
• Run the quality check with the APSE Value/Growth filter — ROCE, earnings growth and cash conversion are your anchors. A stock that passes the chart test but fails the quality filter is a trade, not an investment.
• Remember ratings move: bank analysts upgrade and downgrade constantly, and several names on this list changed rating in October alone. Verify the current chart and rating before acting on anything here.
• Size to the status: CONFIRMED names can carry full position sizes. MIXED names deserve half-size or a staged entry. COMPROMISED names belong on the watchlist or at 1–2% of portfolio maximum. This is a risk-8+ list, so set your exit before you enter.
• Double check and analyse for yourself always. Markets move fast and things can have moved significantly even by the time I finish writing this sentence.

The names on this list range from quality compounders backed by every major bank to businesses where the brokers are well ahead of the chart. The full analysis tells you which is which. The MACD and quality filter in ShareScope are your tools for staying on the right side of that distinction.

MORE AVAILABLE IN THE ALPESH PATEL SPECIAL EDITION NEWSLETTER – SUBSCRIBERS ONLY. EXISTING APSE SUBSCRIBERS PLEASE REFER TO LATEST NEWSLETTER.Want the Full Analysis on All 25 Top-Tier Stocks?— The complete write-up on every name: exact MACD readings, VGI scores, analyst moves, risk flags, and a 12-month chart projection — The full 87-stock watchlist by sector, with a 12-month chart projection for each — Plus APSE filter layouts pre-loaded in ShareScope so you can run the quality screen yourself Upgrade at sharescope.co.uk/alpeshpatel

Alpesh Patel OBE | @alpeshbp | www.alpeshpatel.com/sharescope

www.campaignforamillion.com | www.alpeshpatel.com/shares

This article is for informational and educational purposes only. It does not constitute personalised investment guidance, a financial promotion, or a recommendation to buy or sell any security. Bank analyst ratings are drawn from published research and may change at any time. Price projections referred to are chart-derived trend illustrations, not forecasts or price targets. The value of investments can fall as well as rise and you may receive back less than you invest. All data as of mid-October 2026. Always conduct your own due diligence. Alpesh Patel OBE provides mentoring and education, not regulated financial advice.

This article is for educational purposes only. It is not a recommendation to buy or sell shares or other investments. Do your own research before buying or selling any investment or seek professional financial advice.